There are currently 44 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Systemic Lupus Erythematosus participants are California, Florida, Texas and New York.
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749
Recruiting
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
All
Ages:
12 years and above
Trial Updated:
06/11/2024
Locations: Pinnacle Research Group LLC ., Anniston, Alabama +85 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
All
Ages:
12 years and above
Trial Updated:
06/03/2024
Locations: Providence Medical Center, Burbank, California +125 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249
Recruiting
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: GSK Investigational Site, Anniston, Alabama +112 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422
Recruiting
Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Objective: To test whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with SLE. Eligibility: People aged 18 to 80 years with SLE. Design: Participants will undergo screening. Th... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/31/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
Register for Updates
A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE)
NCT06153095
Recruiting
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-514, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with active, refractory lupus nephritis and systemic lupus erythematosus. IMPT-514 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide. Individual... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: University of California, Los Angeles (UCLA) Medical Center, Los Angeles, California +5 locations
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
Register for Updates
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
NCT06121297
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/29/2024
Locations: University of California Irvine, Orange, California +11 locations
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
Register for Updates
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
NCT06294236
Recruiting
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/22/2024
Locations: University of Colorado, Aurora, Colorado +2 locations
Conditions: Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Register for Updates
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
NCT05798117
Recruiting
The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/17/2024
Locations: Division of Rheumatology Immunology, Birmingham, Alabama +11 locations
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
Register for Updates
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
NCT04751396
Recruiting
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis, Enteropathic Arthritis, Enteropathic Spondylitis
Register for Updates
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696
Recruiting
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/10/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +168 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310
Recruiting
A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
04/26/2024
Locations: Research Site, Phoenix, Arizona +76 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
NCT06378736
Recruiting
Patients with systemic lupus erythematosus (SLE) often experience a frustrating decline of their cognitive skills that includes considerable problems in attention, learning, and memory. This lupus-related cognitive dysfunction (termed SLE-CD) is recognized as the most prevalent of the nineteen neuropsychiatric SLE syndromes, as it affects up to 80% of patients and can significantly decrease their quality of life. The goal is to have tools that can be used for diagnosis and for monitoring respons... Read More
Gender:
Female
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2024
Locations: Northwell Health-Feinstein Insitute, Manhasset, New York
Conditions: Systemic Lupus Erythematosus
Register for Updates